Please Note:
This profile was automatically generated using 6 references found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 6 references found on the Internet. This information has not been verified. Learn more...
Employment History
View...View all 6 references Web References
-
1. ISOPP, the International Society of Oncology Pharmacy Practitioners : CuraGen and TopoTarget Announce Initiation of NCI-sponsored Trial in MDS
isopp.org/tiki-read_article.ph - [Cached]Published on: 2/5/2007 Last Visited: 11/5/2007
The Phase II clinical trial is being led by Amanda Cashen, M.D., Assistant Professor at the Washington School of Medicine in St. Louis, MO. Patients with MDS that have received no more than one prior therapy are eligible for enrollment.
...
Given the promising activity of HDAC inhibitors, and the safety and efficacy profile of PXD101, we are very excited to begin evaluating this agent in the treatment of MDS and look forward to further characterizing its activity and pharmacodynamic profile in this patient population," stated Dr. Cashen. -
2. Oxfordshire Bioscience Network
www.oxfordshirebioscience.com/ - [Cached]Published on: 11/16/2006 Last Visited: 12/3/2006
The Phase II clinical trial is being led by Amanda Cashen, M.D., Assistant Professor at the Washington School of Medicine in St. Louis, MO. Patients with MDS that have received no more than one prior therapy are eligible for en-rolment. -
3. CuraGen - CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial of PXD101 for Myelodysplastic Syndrome
ir.curagen.com/releasedetail.c - [Cached]Published on: 11/16/2006 Last Visited: 12/3/2006
The Phase II clinical trial is being led by Amanda Cashen, M.D., Assistant Professor at the Washington School of Medicine in St. Louis, MO. Patients with MDS that have received no more than one prior therapy are eligible for enrollment.
...
Given the promising activity of HDAC inhibitors, and the safety and efficacy profile of PXD101, we are very excited to begin evaluating this agent in the treatment of MDS and look forward to further characterizing its activity and pharmacodynamic profile in this patient population," stated Dr. Cashen.
